TransThera Sciences (Nanjing). Inc. stock analysis
Want to see HK:2617 full AI Analyst Report?
TransThera Sciences (Nanjing). Inc. (2617) Stock Price & Analysis
2617 Stock Chart & Stats
- Day’s Range
- HKD 7.22 - HKD 7.80
- 52-Week Range
- HKD 7.22 - HKD 221.40
- Previous Close
- HKD 7.58
- Volume
- N/A
- Average Volume (3M)
- 3.18M
- Market Cap
- HKD 2.27B
- Enterprise Value
- HKD 3.65B
- Total Cash (Recent Filing)
- HKD 925.22M
- Total Debt (Recent Filing)
- HKD 5.61M
- Price to Earnings (P/E)
- ―
- Beta
- 2.68
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Very low debt relative to equity limits refinancing and interest-rate exposure, giving the company greater financial flexibility while it develops its pipeline. This conservative capital structure is a durable support compared with a heavily leveraged biotechnology business facing extended development timelines.
Proprietary Drug Development Focus
A focus on proprietary small-molecule therapeutics gives TransThera an identifiable research-led business model rather than dependence on mature commercial products. Advancing candidates through discovery, preclinical work, and clinical trials creates potential for longer-term product ownership and commercialization.
Improving Free Cash Flow Trend
Free cash flow improvement in consecutive years indicates some progress in controlling cash consumption, even though the business remains heavily cash negative. If sustained alongside development activity, this trend could extend the company’s funding runway and moderate the pace of balance-sheet erosion.
Bears Say
No Recent Revenue
Zero revenue in the two most recent annual periods shows that the pipeline has not yet translated into commercial sales. This leaves the company without an operating revenue base to absorb research costs, support recurring cash generation, or demonstrate near-term operating leverage.
Persistent Large Losses
Large and persistent net losses indicate that development spending continues to outweigh any operating contribution. The wider loss in 2025 suggests profitability remains distant, limiting internally generated capital and increasing the importance of successful clinical and commercialization progress.
Material Cash Burn
Substantial annual cash consumption reduces financial flexibility even with low leverage, because ongoing research and clinical development must be funded while operating cash inflows remain absent. Persistent burn can pressure equity and assets and may create future external funding needs.
TransThera Sciences (Nanjing). Inc. News
TransThera Sciences Advances Full Circulation Plan for H Shares After CSRC Filing
TransThera Sciences (Nanjing). Inc. ( ($HK:2617) ) has shared an announcement. TransThera Sciences (Nanjing), Inc., a PRC-based biopharmaceutical company listed on the Hong Kong Stock Exchange, is pursuing capital market
TransThera launches national rollout of first-in-China cholangiocarcinoma drug Yochanra
An announcement from TransThera Sciences (Nanjing). Inc. ( ($HK:2617) ) is now available. TransThera Sciences (Nanjing), Inc. has begun nationwide commercialisation of its core oncology drug Yochanra (tinengotinib tablets) in
TransThera’s Tinengotinib Secures CSCO Guideline Placement for Advanced Biliary Tract Cancers
The latest update is out from TransThera Sciences (Nanjing). Inc. ( ($HK:2617) ). TransThera Sciences has announced that its self-developed multi-target kinase inhibitor YOCHANRA (tinengotinib) has been included as a
TransThera Starts Phase II Trial of Tinengotinib Combo in Resistant Prostate Cancer
TransThera Sciences (Nanjing). Inc. ( ($HK:2617) ) has issued an announcement. TransThera Sciences (Nanjing), Inc., a China-based biopharma company specializing in innovative oncology drugs, is developing tinengotinib, a multi-target kinase
TransThera Wins NMPA Nod for Phase II Lung Cancer Trial of TT-00973 Combo
TransThera Sciences (Nanjing). Inc. ( ($HK:2617) ) just unveiled an announcement. TransThera Sciences (Nanjing), Inc. has received approval from China’s National Medical Products Administration to initiate a multi-center, open-label Phase
2617 FAQ
What was TransThera Sciences (Nanjing). Inc.’s price range in the past 12 months?
What is TransThera Sciences (Nanjing). Inc.’s market cap?
When is TransThera Sciences (Nanjing). Inc.’s upcoming earnings report date?
How were TransThera Sciences (Nanjing). Inc.’s earnings last quarter?
Is TransThera Sciences (Nanjing). Inc. overvalued?
Does TransThera Sciences (Nanjing). Inc. pay dividends?
What is TransThera Sciences (Nanjing). Inc.’s EPS estimate?
How many shares outstanding does TransThera Sciences (Nanjing). Inc. have?
What happened to TransThera Sciences (Nanjing). Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of TransThera Sciences (Nanjing). Inc.?
What is the TipRanks Smart Score and how is it calculated?
TransThera Sciences (Nanjing). Inc. Stock Smart Score
Company Description
TransThera Sciences (Nanjing). Inc.
TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a MTK inhibitor that is in clinical stage for the treatment of recurrent or refractory drug-resistant solid tumors. It also develops TT-00973, a kinase inhibitor for treating various cancers; TT-01488, a BTK inhibitor for the treatment of B-cell lymphoma; TT-01688, an oral S1P1 modulator for treating various inflammatory diseases; TT-00920, an oral PDE9 inhibitor used for treating central nervous system diseases; TT-01025, an oral irreversible VAP-1 inhibitor designed for the treatment of NASH; and TT-02332, a NLRP3 inhibitor for metabolic and inflammatory diseases. The company has a collaboration with Neurocrine Biosciences, Inc. to develop NLRP3 inhibitors for multiple disease. TransThera Sciences (Nanjing), Inc. was formerly known as Nanjing TransThera Biosciences Co. Ltd. and changed its name to TransThera Sciences (Nanjing), Inc. in July 2021. The company was incorporated in 2014 and is headquartered in Nanjing, China.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Yong Qian Wu
- Employees
- 132
- Website
- www.transthera.com
- Address
- Building 9, Accelerator Phase 2, Nanjing, JS, 210032, CN
TransThera Sciences (Nanjing). Inc. (2617) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 1 | 15 |
| Technical Analysis | 6 | 1 | 3 |
| Moving Averages | 0 | 0 | 12 |









